Topic

Principal at Clarion, and Head of Market Access & Pricing

Articles

This article provides an overview of potential tools being explored in Germany by Health Insurance Funds to better control drug prices and healthcare spend, offering insight into which measure may be implemented.

Prospective Measures to Combat Rising Drug Prices in Germany

Ira Studin, PhD, MPH, is president of Stellar Managed Care Consulting, a pharma busines strategies firm in Cherry Hill, New Jersey. He has written Strategic Healthcare Management and numerous articles in healthcare business journals. He can be reached at istudin@stellarmc.com

Tackling the subjective limits of value proposition.

The Case for Elevating a Brand’s Price Proposition 

Assessing the road ahead for Chinese biotech.

Why Patient-Centric Innovation Holds the Key to Long-Term Business Success for Companies in China’s Booming Biotech Sector 

Planning for Second to Market in Orphan Disease Space

Forging effective partnerships with local companies is particularly important when entering Brazil’s pharma market. Sameer Kolhe reports.

Partnerships Are Key to Niche Markets in Brazil

Director, Advisory Services, MMIT (Managed Markets Insight & Technology)

New technology forces industry to increase urgency.

Market Access Speed Is the Next Critical Differentiator for Pharma Manufacturers

Potential for quality equivalent to economies of scale.

Playing the Long Game on Tighter Than Label Coverage 

Emerging limits of one-year payer time frames.

Could Time Be the Next New Element in Pharma Revenue?

Member of the Executive Committee of Bayer AG’s Pharmaceuticals Division and Head of the Oncology Strategic Business Unit

Scientific advances are benefiting cancer patients, but it will take a pandemic-like response to ensure patients everywhere have access.